These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 30055238

  • 1. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
    Tandberg DJ, Cui Y, Rushing CN, Hong JC, Ackerson BG, Marin D, Zhang X, Czito BG, Willett CW, Palta M.
    Int J Radiat Oncol Biol Phys; 2018 Nov 15; 102(4):1002-1007. PubMed ID: 30055238
    [Abstract] [Full Text] [Related]

  • 2. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V, Lucey JA, Duffy GJ, Wilson L, McNamara L, Keogan M, Gillham C, Reynolds JV.
    J Nucl Med; 2010 Dec 15; 51(12):1863-9. PubMed ID: 21078796
    [Abstract] [Full Text] [Related]

  • 3. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, Busch OR, Tilanus HW, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Cuesta MA, Ten Kate FJ, Pruim J, van Dekken H, Bergman JJ, Sloof GW, van Lanschot JJ.
    Ann Surg; 2011 Jan 15; 253(1):56-63. PubMed ID: 21233607
    [Abstract] [Full Text] [Related]

  • 4. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S, Kligerman S, Chen W, Lu M, Kim G, Feigenberg S, D'Souza WD, Suntharalingam M, Lu W.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1375-82. PubMed ID: 23219566
    [Abstract] [Full Text] [Related]

  • 5. Detecting interval metastases and response assessment using 18F-FDG PET/CT after neoadjuvant chemoradiotherapy for esophageal cancer.
    Stiekema J, Vermeulen D, Vegt E, Voncken FE, Aleman BM, Sanders J, Boot H, van Sandick JW.
    Clin Nucl Med; 2014 Oct 01; 39(10):862-7. PubMed ID: 25140549
    [Abstract] [Full Text] [Related]

  • 6. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
    Kukar M, Alnaji RM, Jabi F, Platz TA, Attwood K, Nava H, Ben-David K, Mattson D, Salerno K, Malhotra U, Kanehira K, Gannon J, Hochwald SN.
    JAMA Surg; 2015 Jun 01; 150(6):555-62. PubMed ID: 25902198
    [Abstract] [Full Text] [Related]

  • 7. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment 18F-FDG PET/CT Imaging.
    Beukinga RJ, Hulshoff JB, van Dijk LV, Muijs CT, Burgerhof JGM, Kats-Ugurlu G, Slart RHJA, Slump CH, Mul VEM, Plukker JTM.
    J Nucl Med; 2017 May 01; 58(5):723-729. PubMed ID: 27738011
    [Abstract] [Full Text] [Related]

  • 8. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH, Killoran JH, Kim CK, Hornick JL, Nowak JA, Enzinger PC, Mamon HJ.
    Ann Nucl Med; 2018 Apr 01; 32(3):165-174. PubMed ID: 29332233
    [Abstract] [Full Text] [Related]

  • 9. Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation.
    Arnett ALH, Merrell KW, Macintosh EM, James SE, Nathan MA, Shen KR, Ravi K, Neben Wittich MA, Haddock MG, Hallemeier CL.
    J Thorac Oncol; 2017 Jan 01; 12(1):121-128. PubMed ID: 27569732
    [Abstract] [Full Text] [Related]

  • 10. [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.
    Vallböhmer D, Hölscher AH, Dietlein M, Bollschweiler E, Baldus SE, Mönig SP, Metzger R, Schicha H, Schmidt M.
    Ann Surg; 2009 Dec 01; 250(6):888-94. PubMed ID: 19953708
    [Abstract] [Full Text] [Related]

  • 11. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G, Petyt G, Duhamel A, Mirabel X, Huglo D, Mariette C.
    Ann Surg; 2013 Jul 01; 258(1):66-76. PubMed ID: 23470576
    [Abstract] [Full Text] [Related]

  • 12. The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer.
    van Rossum PS, Fried DV, Zhang L, Hofstetter WL, van Vulpen M, Meijer GJ, Court LE, Lin SH.
    J Nucl Med; 2016 May 01; 57(5):691-700. PubMed ID: 26795288
    [Abstract] [Full Text] [Related]

  • 13. Prediction of Response to Neoadjuvant Chemotherapy and Radiation Therapy with Baseline and Restaging 18F-FDG PET Imaging Biomarkers in Patients with Esophageal Cancer.
    Beukinga RJ, Hulshoff JB, Mul VEM, Noordzij W, Kats-Ugurlu G, Slart RHJA, Plukker JTM.
    Radiology; 2018 Jun 01; 287(3):983-992. PubMed ID: 29533721
    [Abstract] [Full Text] [Related]

  • 14. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using 18F-FDG PET/CT and DW-MRI: A Prospective Multicenter Study.
    Borggreve AS, Goense L, van Rossum PSN, Heethuis SE, van Hillegersberg R, Lagendijk JJW, Lam MGEH, van Lier ALHMW, Mook S, Ruurda JP, van Vulpen M, Voncken FEM, Aleman BMP, Bartels-Rutten A, Ma J, Fang P, Musall BC, Lin SH, Meijer GJ.
    Int J Radiat Oncol Biol Phys; 2020 Apr 01; 106(5):998-1009. PubMed ID: 31987972
    [Abstract] [Full Text] [Related]

  • 15. Ability of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography to Predict Outcomes of Neoadjuvant Chemoradiotherapy Followed by Surgical Treatment for Esophageal Squamous Cell Carcinoma.
    Hamai Y, Hihara J, Emi M, Furukawa T, Yamakita I, Kurokawa T, Okada M.
    Ann Thorac Surg; 2016 Oct 01; 102(4):1132-9. PubMed ID: 27319990
    [Abstract] [Full Text] [Related]

  • 16. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
    Valkema MJ, Noordman BJ, Wijnhoven BPL, Spaander MCW, Biermann K, Lagarde SM, Bennink RJ, Schreurs WMJ, Roef MJ, Hobbelink MGG, Janssen MJR, Graven LH, van Lanschot JJB, Valkema R.
    J Nucl Med; 2019 Nov 01; 60(11):1553-1559. PubMed ID: 30877177
    [Abstract] [Full Text] [Related]

  • 17. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
    Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA.
    Radiother Oncol; 2008 Dec 01; 89(3):278-86. PubMed ID: 18701180
    [Abstract] [Full Text] [Related]

  • 18. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
    Sakane M, Tatsumi M, Hori M, Onishi H, Tsuboyama T, Nakamoto A, Ota T, Eguchi H, Wakasa K, Hatazawa J, Tomiyama N.
    Eur J Radiol; 2017 Sep 01; 94():64-69. PubMed ID: 28712692
    [Abstract] [Full Text] [Related]

  • 19. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
    Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, Mueller PR.
    Ann Thorac Surg; 2008 Oct 01; 86(4):1131-8. PubMed ID: 18805147
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of 18f-Fluorodeoxyglucose Positron Emission Tomography for Predicting the Pathological Response of Neoadjuvant Chemoradiotherapy for T4 Esophageal Squamous Cell Carcinoma.
    Sakai M, Sohda M, Miyazaki T, Honjo H, Hara K, Ozawa D, Suzuki S, Tanaka N, Yokobori T, Kuwano H.
    Hepatogastroenterology; 2015 Jun 01; 62(140):898-901. PubMed ID: 26902024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.